...
首页> 外文期刊>Journal of Clinical Oncology >Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognos
【24h】

Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognos

机译:暴露于烷基化剂后,与治疗相关的骨髓增生异常和急性髓细胞性白血病中,p53杂合性丧失的突变很常见,并且与5q的缺失或丧失,复杂的核型和不良的预后密切相关。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To study mutations and loss of heterozygosity (LOH) of p53 in therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML). PATIENTS AND METHODS: Fifty-two unselected patients with t-MDS and 25 patients with t-AML were studied by polymerase chain reaction (PCR)-single-strand conformational polymorphism (SSCP) at the DNA level and by reverse transcriptase (RT)-PCR-SSCP at the mRNA level, and cases with aberrant SSCP patterns were sequenced. RESULTS: Somatically acquired mutations of p53 were observed in 21 of 77 cases of t-MDS or t-AML, and 19 of these 21 patients had received alkylating agents. Single-base substitutions at A:T pairs were more common in t-MDS and t-AML, whereas single-base substitutions at G:C pairs are most common in MDS and AML de novo and in solid tumors. Six patients demonstrated a cytogenetic loss of 17p13, and these six and an additional nine patients with p53 mutations demonstrated LOH of p53 at the DNA or mRNA level. This suggests a cytogenetic loss of the normal p53 allele in these nine cases combined with duplication of the homologous chromosome 17 carrying the mutated p53 allele. Mutations of p53 were significantly associated with deletion or loss of 5q (P <.0001) and a complex karyotype (P =.0001), but surprisingly were not associated with deletion or loss of 7q (P =.73), and were infrequent in patients with balanced chromosome translocations (P =.03). Mutations of p53 were more common in older patients (P =.036) and were associated with an extremely poor prognosis (P =.014), apparently restricted to the 15 cases with LOH of p53 ( P =.046). CONCLUSION: Mutations with loss of function of p53 are significantly associated with deletion or loss of 5q in t-MDS and t-AML after previous treatment with alkylating agents and are associated with genetic instability.
机译:目的:研究与治疗相关的骨髓增生异常(t-MDS)和急性髓细胞性白血病(t-AML)中p53的突变和杂合性丧失(LOH)。病人与方法:通过DNA聚合酶链反应(PCR)-单链构象多态性(SSCP)和逆转录酶(RT)-研究了52例未选择的t-MDS患者和25例t-AML患者。对mRNA水平的PCR-SSCP以及异常SSCP模式的病例进行测序。结果:在77例t-MDS或t-AML患者中,有21例发生了体细胞获得性p53突变,在这21例患者中有19例接受了烷化剂治疗。在t-MDS和t-AML中,A:T对的单碱基取代更为常见,而在MDS和AML从头以及实体瘤中,G:C对的单碱基取代最为常见。 6名患者表现出17p13的细胞遗传学丧失,这6名以及另外9名具有p53突变的患者在DNA或mRNA水平上显示p53的LOH。这表明在这九种情况下正常p53等位基因的细胞遗传学丧失与携带突变的p53等位基因的同源染色体17的复制相结合。 p53突变与5q的缺失或缺失显着相关(P <.0001)和复杂的核型(P = .0001),但令人惊讶的是与7q的缺失或缺失无关(P = .73),并且很少见具有平衡染色体易位的患者(P = .03)。 p53突变在老年患者中更为常见(P = .036),并且与预后极差有关(P = .014),显然仅限于15例p53 LOH患者(P = .046)。结论:p53功能丧失的突变与先前用烷基化剂治疗后的t-MDS和t-AML中5q的缺失或丧失显着相关,并且与遗传不稳定有关。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号